Literature DB >> 16437592

Bifunctional chimeric SuperCD suicide gene -YCD: YUPRT fusion is highly effective in a rat hepatoma model.

Florian Graepler1, Marie-Luise Lemken, Wolfgang A Wybranietz, Ulrike Schmidt, Irina Smirnow, Christine D Gross, Martin Spiegel, Andrea Schenk, Hansjörg Graf, Ulrike A Lauer, Reinhard Vonthein, Michael Gregor, Sorin Armeanu, Michael Bitzer, Ulrich M Lauer.   

Abstract

AIM: To investigate the effects of catalytically superior gene-directed enzyme prodrug therapy systems on a rat hepatoma model.
METHODS: To increase hepatoma cell chemosensitivity for the prodrug 5-fluorocytosine (5-FC), we generated a chimeric bifunctional SuperCD suicide gene, a fusion of the yeast cytosine deaminase (YCD) and the yeast uracil phosphoribosyltransferase (YUPRT) gene.
RESULTS: In vitro stably transduced Morris rat hepatoma cells (MH) expressing the bifunctional SuperCD suicide gene (MH SuperCD) showed a clearly marked enhancement in cell killing when incubated with 5-FC as compared with MH cells stably expressing YCD solely (MH YCD) or the cytosine deaminase gene of bacterial origin (MH BCD), respectively. In vivo, MH SuperCD tumors implanted both subcutaneously as well as orthotopically into the livers of syngeneic ACI rats demonstrated significant tumor regressions (P<0.01) under both high dose as well as low dose systemic 5-FC application, whereas MH tumors without transgene expression (MH naive) showed rapid progression. For the first time, an order of in vivo suicide gene effectiveness (SuperCD>> YCD>>BCD>>>negative control) was defined as a result of a direct in vivo comparison of all three suicide genes.
CONCLUSION: Bifunctional SuperCD suicide gene expression is highly effective in a rat hepatoma model, thereby significantly improving both the therapeutic index and the efficacy of hepatocellular carcinoma killing by fluorocytosine.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16437592      PMCID: PMC4717030          DOI: 10.3748/wjg.v11.i44.6910

Source DB:  PubMed          Journal:  World J Gastroenterol        ISSN: 1007-9327            Impact factor:   5.742


  48 in total

Review 1.  Replication-selective virotherapy for cancer: Biological principles, risk management and future directions.

Authors:  D Kirn; R L Martuza; J Zwiebel
Journal:  Nat Med       Date:  2001-07       Impact factor: 53.440

Review 2.  Protein transduction: an alternative to genetic intervention?

Authors:  K G Ford; B E Souberbielle; D Darling; F Farzaneh
Journal:  Gene Ther       Date:  2001-01       Impact factor: 5.250

3.  Double suicide gene (cytosine deaminase and herpes simplex virus thymidine kinase) but not single gene transfer allows reliable elimination of tumor cells in vivo.

Authors:  W Uckert; T Kammertöns; K Haack; Z Qin; J Gebert; D J Schendel; T Blankenstein
Journal:  Hum Gene Ther       Date:  1998-04-10       Impact factor: 5.695

4.  Target gene therapy for alpha-fetoprotein-producing hepatocellular carcinoma by E1B55k-attenuated adenovirus.

Authors:  M Ohashi; F Kanai; K Tateishi; H Taniguchi; P A Marignani; Y Yoshida; Y Shiratori; H Hamada; M Omata
Journal:  Biochem Biophys Res Commun       Date:  2001-03-30       Impact factor: 3.575

5.  A blood-tumor barrier limits gene transfer to experimental liver cancer: the effect of vasoactive compounds.

Authors:  R Bilbao; M Bustos; P Alzuguren; M J Pajares; M Drozdzik; C Qian; J Prieto
Journal:  Gene Ther       Date:  2000-11       Impact factor: 5.250

6.  Gene therapy of metastatic colon carcinoma: regression of multiple hepatic metastases by adenoviral expression of bacterial cytosine deaminase.

Authors:  A Block; C T Freund; S H Chen; K P Nguyen; M Finegold; E Windler; S L Woo
Journal:  Cancer Gene Ther       Date:  2000-03       Impact factor: 5.987

7.  New colorimetric cytotoxicity assay for anticancer-drug screening.

Authors:  P Skehan; R Storeng; D Scudiero; A Monks; J McMahon; D Vistica; J T Warren; H Bokesch; S Kenney; M R Boyd
Journal:  J Natl Cancer Inst       Date:  1990-07-04       Impact factor: 13.506

8.  Evidence for conversion of 5-fluorocytosine to 5-fluorouracil in humans: possible factor in 5-fluorocytosine clinical toxicity.

Authors:  R B Diasio; D E Lakings; J E Bennett
Journal:  Antimicrob Agents Chemother       Date:  1978-12       Impact factor: 5.191

9.  A first step in the development of gene therapy for colorectal carcinoma: cloning, sequencing, and expression of Escherichia coli cytosine deaminase.

Authors:  E A Austin; B E Huber
Journal:  Mol Pharmacol       Date:  1993-03       Impact factor: 4.436

10.  Metabolism of 5-fluorocytosine to 5-fluorouracil in human colorectal tumor cells transduced with the cytosine deaminase gene: significant antitumor effects when only a small percentage of tumor cells express cytosine deaminase.

Authors:  B E Huber; E A Austin; C A Richards; S T Davis; S S Good
Journal:  Proc Natl Acad Sci U S A       Date:  1994-08-16       Impact factor: 11.205

View more
  13 in total

1.  In vitro gene targeting in human hepatoblastoma.

Authors:  Steven W Warmann; Sorin Armeanu; Heike Frank; Heike Buck; Florian Graepler; Marie-Luise Lemken; Heike Heitmann; Guido Seitz; Ulrich M Lauer; Michael Bitzer; Jörg Fuchs
Journal:  Pediatr Surg Int       Date:  2006-01       Impact factor: 1.827

2.  Targeted cytosine deaminase-uracil phosphoribosyl transferase suicide gene therapy induces small cell lung cancer-specific cytotoxicity and tumor growth delay.

Authors:  Camilla L Christensen; Torben Gjetting; Thomas T Poulsen; Frederik Cramer; Jack A Roth; Hans S Poulsen
Journal:  Clin Cancer Res       Date:  2010-04-06       Impact factor: 12.531

3.  Potent bystander effect and tumor tropism in suicide gene therapy using stem cells from human exfoliated deciduous teeth.

Authors:  Makoto Horikawa; Shinichiro Koizumi; Tomoya Oishi; Taisuke Yamamoto; Masashi Ikeno; Masahiko Ito; Tomohiro Yamasaki; Shinji Amano; Tetsuro Sameshima; Yasuyuki Mitani; Yoshihiro Otani; Yuanqing Yan; Tetsuro Suzuki; Hiroki Namba; Kazuhiko Kurozumi
Journal:  Cancer Gene Ther       Date:  2022-09-08       Impact factor: 5.854

4.  Advances in the mechanisms of action of cancer-targeting oncolytic viruses.

Authors:  Cun-Zhi Lin; Gui-Ling Xiang; Xin-Hong Zhu; Lu-Lu Xiu; Jia-Xing Sun; Xiao-Yuan Zhang
Journal:  Oncol Lett       Date:  2018-01-19       Impact factor: 2.967

5.  Novel strong tissue specific promoter for gene expression in human germ cells.

Authors:  Denis Kuzmin; Elena Gogvadze; Roman Kholodenko; Dawid P Grzela; Maxim Mityaev; Tatyana Vinogradova; Eugene Kopantzev; Galina Malakhova; Maria Suntsova; Dmitry Sokov; Zoltán Ivics; Anton Buzdin
Journal:  BMC Biotechnol       Date:  2010-08-17       Impact factor: 2.563

6.  Abrogation of microsatellite-instable tumors using a highly selective suicide gene/prodrug combination.

Authors:  Cristina Ferrás; Joachim A F Oude Vrielink; Johan W A Verspuy; Hein te Riele; Anastasia Tsaalbi-Shtylik; Niels de Wind
Journal:  Mol Ther       Date:  2009-05-26       Impact factor: 11.454

7.  A novel armed oncolytic measles vaccine virus for the treatment of cholangiocarcinoma.

Authors:  Sebastian Lange; Johanna Lampe; Sascha Bossow; Martina Zimmermann; Wolfgang Neubert; Michael Bitzer; Ulrich M Lauer
Journal:  Hum Gene Ther       Date:  2013-05       Impact factor: 5.695

8.  Innate immune defense defines susceptibility of sarcoma cells to measles vaccine virus-based oncolysis.

Authors:  Susanne Berchtold; Johanna Lampe; Timo Weiland; Irina Smirnow; Sabine Schleicher; Rupert Handgretinger; Hans-Georg Kopp; Jeanette Reiser; Frank Stubenrauch; Nora Mayer; Nisar P Malek; Michael Bitzer; Ulrich M Lauer
Journal:  J Virol       Date:  2013-01-09       Impact factor: 5.103

9.  Comparative analysis of enzyme and pathway engineering strategies for 5FC-mediated suicide gene therapy applications.

Authors:  A J Johnson; A Ardiani; M Sanchez-Bonilla; M E Black
Journal:  Cancer Gene Ther       Date:  2011-03-11       Impact factor: 5.987

10.  Promoters with cancer cell-specific activity for melanoma gene therapy.

Authors:  V V Pleshkan; I V Alekseenko; M V Zinovyeva; T V Vinogradova; E D Sverdlov
Journal:  Acta Naturae       Date:  2011-04       Impact factor: 1.845

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.